GlassScriptPhysician profile
Matthew D Thompson
NPI 1619989266
$10,290.60
in general payments reported to CMS, 2019-2025
56 companies · $1,387 in 2025
The $1,387 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,137 · 2020: $1,912 · 2021: $1,596 · 2022: $1,043 · 2023: $1,876 · 2024: $1,341 · 2025: $1,387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,495 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,495.31 |
| Education | $108.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,734.28 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $1,048.19 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $948.56 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Antares Pharma, INC. | $706.30 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Glaxosmithkline, LLC. | $552.64 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $527.29 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $406.58 | 2019-2025 | |
| Clarus Therapeutics INC. | $326.17 | 2021 | |
| Upsher-Smith Laboratories LLC | $309.35 | 2019-2023 | |
| Currax Pharmaceuticals LLC | $281.81 | 2020-2023 | Nexletol, Onzetra Xsail, Contrave |
| Amgen INC. | $264.88 | 2019-2024 | Repatha, Otezla |
| Aytu Biopharma, INC. | $259.71 | 2019-2020 | |
| Allergan, INC. | $208.30 | 2019-2020 | |
| Shield Therapeutics INC | $176.11 | 2023-2024 | Accrufer |
| Axsome Therapeutics, INC. | $173.95 | 2023-2025 | Auvelity |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.